Prognostic factors for patients treated with abiraterone

Detalhes bibliográficos
Autor(a) principal: Alvim, Cecilia
Data de Publicação: 2020
Outros Autores: Mansinho, André, Paiva, Rita S., Brás, Raquel, Semedo, Patrícia M., Lobo-Martins, Soraia, da Ponte, Carolina B., Macedo, Daniela, Ribeiro, Maria Leonor, dos Reis, José P, Fernandes, Isabel, Costa, Luis
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/50320
Resumo: © Cecilia Melo Alvim. This work is licensed under the Creative Commons Attribution4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
id RCAP_8e54aa2214e36abdf0c9764386679832
oai_identifier_str oai:repositorio.ul.pt:10451/50320
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Prognostic factors for patients treated with abirateroneAbiraterone acetateMetastatic castration-resistant prostate cancerProstate-specific antigen response© Cecilia Melo Alvim. This work is licensed under the Creative Commons Attribution4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evaluation of patients with mCRPC treated with AA. Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10-0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14-0.41; p < 0.001). Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA.Future Science Ltd.Repositório da Universidade de LisboaAlvim, CeciliaMansinho, AndréPaiva, Rita S.Brás, RaquelSemedo, Patrícia M.Lobo-Martins, Soraiada Ponte, Carolina B.Macedo, DanielaRibeiro, Maria Leonordos Reis, José PFernandes, IsabelCosta, Luis2021-12-09T16:46:26Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/50320engFuture Sci OA. 2019 Dec 12;6(2):FSO4362056-562310.2144/fsoa-2019-0079info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-11-20T18:10:25Zoai:repositorio.ul.pt:10451/50320Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-11-20T18:10:25Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Prognostic factors for patients treated with abiraterone
title Prognostic factors for patients treated with abiraterone
spellingShingle Prognostic factors for patients treated with abiraterone
Alvim, Cecilia
Abiraterone acetate
Metastatic castration-resistant prostate cancer
Prostate-specific antigen response
title_short Prognostic factors for patients treated with abiraterone
title_full Prognostic factors for patients treated with abiraterone
title_fullStr Prognostic factors for patients treated with abiraterone
title_full_unstemmed Prognostic factors for patients treated with abiraterone
title_sort Prognostic factors for patients treated with abiraterone
author Alvim, Cecilia
author_facet Alvim, Cecilia
Mansinho, André
Paiva, Rita S.
Brás, Raquel
Semedo, Patrícia M.
Lobo-Martins, Soraia
da Ponte, Carolina B.
Macedo, Daniela
Ribeiro, Maria Leonor
dos Reis, José P
Fernandes, Isabel
Costa, Luis
author_role author
author2 Mansinho, André
Paiva, Rita S.
Brás, Raquel
Semedo, Patrícia M.
Lobo-Martins, Soraia
da Ponte, Carolina B.
Macedo, Daniela
Ribeiro, Maria Leonor
dos Reis, José P
Fernandes, Isabel
Costa, Luis
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Alvim, Cecilia
Mansinho, André
Paiva, Rita S.
Brás, Raquel
Semedo, Patrícia M.
Lobo-Martins, Soraia
da Ponte, Carolina B.
Macedo, Daniela
Ribeiro, Maria Leonor
dos Reis, José P
Fernandes, Isabel
Costa, Luis
dc.subject.por.fl_str_mv Abiraterone acetate
Metastatic castration-resistant prostate cancer
Prostate-specific antigen response
topic Abiraterone acetate
Metastatic castration-resistant prostate cancer
Prostate-specific antigen response
description © Cecilia Melo Alvim. This work is licensed under the Creative Commons Attribution4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2021-12-09T16:46:26Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/50320
url http://hdl.handle.net/10451/50320
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Future Sci OA. 2019 Dec 12;6(2):FSO436
2056-5623
10.2144/fsoa-2019-0079
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Future Science Ltd.
publisher.none.fl_str_mv Future Science Ltd.
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817549161338241024

Registros relacionados